Phase I trial of the programmed death receptor 1 (PD-1) inhibitor, BI 754091, in patients (pts) with advanced solid tumors.

被引：2
|
作者：
Johnson, Melissa Lynne
Patel, Manish R.
Siu, Lillian L.
Kozloff, Mark
Aljumaily, Raid
Vaishampayan, Ulka N.
Elgadi, Mabrouk M.
Ge, Miaomiao
Duffy, Christine
Graeser, Ralph
Khedkar, Sheetal Vinay
Jones, Suzanne Fields
Burris, Howard A.
机构：
[1] PLLC, Sarah Cannon Res Inst, Tennessee Oncol, Nashville, TN USA
[2] Sarah Cannon Res Inst, Florida Canc Specialists, Sarasota, FL USA
[3] Princess Margaret Canc Ctr, Toronto, ON, Canada
[4] Ingalls Mem Hosp, Harvey, IL USA
[5] Oklahoma Univ, Med Ctr, Stephenson Canc Ctr, Oklahoma City, OK USA
[6] Karmanos Canc Ctr, Detroit, MI USA
[7] Boehringer Ingelheim GmbH & Co KG, Burlington, ON, Canada
[8] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT USA
[9] Boehringer Ingelheim Pharma GmbH & Co KG, Rhein, Germany
[10] Sarah Cannon Res Inst, Nashville, TN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 05期
关键词：
D O I：
10.1200/JCO.2018.36.5_suppl.212
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
212
引用
收藏
页数：1
相关论文
共 50 条
  • [21] NIVOLUMAB (ANTI-PROGRAMMED DEATH-1 [PD-1]; BMS-936558) IN PATIENTS (PTS) WITH ADVANCED SOLID TUMORS: CLINICAL ACTIVITY, SAFETY, AND MOLECULAR MARKERS
    Feltquate, D. M.
    ANNALS OF ONCOLOGY, 2013, 24 : 7 - 7
  • [22] First in human phase I trial of the PARP inhibitor AG-014699 with temozolomide (TMZ) in patients (pts) with advanced solid tumors.
    Plummer, R
    Middleton, M
    Wilson, R
    Jones, C
    Evans, J
    Robson, L
    Steinfeldt, H
    Kaufman, R
    Reich, S
    Calvert, AH
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 208S - 208S
  • [23] Phase I trial of irinotecan and epirubicin in patients with advanced solid tumors.
    Gold, PJ
    Refice, S
    West, H
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 164S - 164S
  • [24] Phase I trial of volasertib (BI 6727), a polo-like kinase 1 (Plk1) inhibitor, in combination with cisplatin or carboplatin in patients with advanced solid tumors.
    Deleporte, A.
    Dumez, H.
    Awada, A.
    Costermans, J.
    Meeus, M.
    Berghmans, T.
    Kaci, M. Ould
    Juhel, N.
    Berge, A.
    Taube, T.
    Schoeffski, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [25] Phase I first-in-man trial of a novel bromodomain and extra-terminal domain (BET) inhibitor (BI 894999) in patients (Pts) with advanced solid tumors.
    Aftimos, Philippe Georges
    Bechter, Oliver
    Awada, Ahmad
    Jungels, Christiane
    Dumez, Herlinde
    Huyvaert, Nathalie
    Costermans, Jo
    Lee, Chooi
    Meeus, Marie-Anne
    Burkard, Ute
    Musa, Hanny
    Zhao, Yihua
    Schoffski, Patrick
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [26] Outcomes of Programmed Cell Death Protein 1 (PD-1) and Programmed Death-Ligand 1 (PD-L1) Inhibitor Therapy in HIV Patients with Advanced Cancer
    Bari, Shahla
    Muzaffar, Jameel
    Chan, Austin
    Jain, Sanjay R.
    Haider, Ahmad M.
    Curry, Marjorie Adams
    Hostler, Christopher J.
    JOURNAL OF ONCOLOGY, 2019, 2019
  • [27] Ezabenlimab (BI 754091), an anti-PD-1 antibody, in patients with advanced solid tumours
    Manish R. Patel
    Melissa Johnson
    Ira Winer
    Hendrik-Tobias Arkenau
    Natalie Cook
    Vanessa Samouëlian
    Raid Aljumaily
    Shigehisa Kitano
    Christine Duffy
    Miaomiao Ge
    Mabrouk Elgadi
    Lillian L. Siu
    Cancer Immunology, Immunotherapy, 73
  • [28] Inhibitor of apoptosis proteins (IAP) inhibitor APG-1387 monotherapy or in combination with programmed cell death 1 (PD-1) inhibitor toripalimab inpatients with advanced solid tumors: results from two phase I trials
    Liu, F. -R.
    Wei, X. -L.
    Feng, W. -N.
    Zhao, H. -Y.
    Zhang, Y.
    Wang, Z. -Q.
    Zhang, D. -S.
    Wang, F. -H.
    Yang, S.
    Pan, W.
    Men, L.
    Wang, H.
    Liang, E.
    Wang, C.
    Yang, D.
    Zhai, Y.
    Qiu, M. -Z.
    Xu, R. -H.
    ESMO OPEN, 2024, 9 (08)
  • [29] Phase I trial with farnesyltransferase inhibitor R115777 in patients (pts) with advanced solid tumors
    Punt, CJA
    Peters, M
    van Maanen, L
    van de Walle, B
    Bol, C
    Willems, L
    Horak, I
    Palmer, P
    Wagener, DJT
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S291 - S291
  • [30] Ezabenlimab (BI 754091), an anti-PD-1 antibody, in patients with advanced solid tumours
    Patel, Manish R.
    Johnson, Melissa
    Winer, Ira
    Arkenau, Hendrik-Tobias
    Cook, Natalie
    Samouelian, Vanessa
    Aljumaily, Raid
    Kitano, Shigehisa
    Duffy, Christine
    Ge, Miaomiao
    Elgadi, Mabrouk
    Siu, Lillian L.
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2024, 73 (05)
12345